Search for content, post, videos

Biovian and Remedium collaborate on AAV gene therapy

The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.